Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 28 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/1/1994


1.		Phase I/II Study of Escalating-Dose IL-6 with GM-CSF Prior to ABMT, with Randomization to IL-6/GM-CSF vs GM-CSF Following ABMT, for Nonhematologic Malignancies (Summary Last Modified 11/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over								FHCRC-760.1 NCI-V94-0403

Last Modified: 3/1/1997


2.		Phase I/II Study of IL-6 for Relapsed or Refractory AML (Summary Last Modified 03/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				over 18				NCI				RPMI-DS-9422 NCI-T93-0177D, T93-0177

Last Modified: 3/1/1997


3.		Phase I/II Study of Escalating IL-6 with GM-CSF/EPO for Myelodysplastic Syndrome (Summary Last Modified 03/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				RPMI-DS-9429 NCI-T94-0072D, T94-0072

Last Modified: 8/1/1999


4.		Phase II Pilot Study of MDR-1 Retrovirus-Transduced Peripheral Blood Stem Cells for Chemoprotection During Therapy for Advanced Breast Cancer (Summary Last Modified 08/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 to 60				NCI				MDA-DM-94028 NCI-T95-0064D, T95-0064

Last Modified: 11/13/2007


5.		Phase II Pilot Study of High-Dose Ifosfamide/Carboplatin/Etoposide (ICE) Followed by Transplantation with neo-r-Transduced Autologous Bone Marrow and PBSC for Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 to 60				NCI				NCI-92-C-0161I NCI-MB-294, NCI-T92-0018N, T92-0018

Last Modified: 8/1/1993


6.		Phase II Study of IL-6 Administered by 120-Hour Continuous Intravenous Infusion in Patients with Advanced Renal Cell Carcinoma (Summary Last Modified 08/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				IDB-IL-6/RENAL NCI-T93-0038N, T93-0038

Last Modified: 10/1/1993


7.		Phase II Study of IL-6 Administered by 1-Hour Intravenous Infusion in Patients with Metastatic or Locally Advanced Melanoma (Summary Last Modified 10/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				IDB-IL-6/MELANOMA NCI-T93-0049N, T93-0049

Last Modified: 11/1/1994


8.		Phase II Study of IL-6 for Metastatic Renal Cell Cancer (Summary Last Modified 11/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over								CCF-RPC-3272F NCI-B93-0005, B93-0005

Last Modified: 12/1/1993


9.		Phase II Study of IL-6 in Patients with Smoldering Relapse of AML (Summary Last Modified 12/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				17 and over				NCI				MDA-DM-93081 NCI-T93-0130C, T93-0130

Last Modified: 7/1/1994


10.		Phase I Study of IL-3/IL-6 in Patients with Myelodysplastic Syndrome (Summary Last Modified 07/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				DFCI-93079 NCI-T93-0001D, T93-0001

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute